AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00872001
Drug: Acadesine
RxNorm normalized name: acadesine
DrugBank: Acadesine (DB04944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
Trial: NCT06012565
Drug: KAND567
RxNorm normalized name: KAND567
DrugBank: KAND567 (DB16511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).
Trial: NCT06012565
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
Trial: NCT01359618
Drug: TC-5214
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, oral tablets
Trial: NCT01359618
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, oral encapsulated tablet
Trial: NCT00258440
Drug: Interval Dosing
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
Trial: NCT03591757
Drug: Tolcapone
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
Trial: NCT00260819
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
Trial: NCT00115219
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02172300
Drug: Tiotropium inhalation capsules
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01780129
Drug: Polydatin Injectable
RxNorm normalized name: polydatin
DrugBank: Polydatin (DB11263)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
Trial: NCT00562978
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00152971
Drug: Dabigatran Dose 1 - day 2 to completion
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose regimen taken once daily
Trial: NCT00152971
Drug: Dabigatran Dose 1 - day 1
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose regimen taken once daily
Trial: NCT00152971
Drug: Dabigatran Dose 2 - day 2 to completion
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose regimen taken once daily
Trial: NCT00152971
Drug: Dabigatran Dose 2 - day 1
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose regimen taken once daily
Trial: NCT00152971
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg subcutaneously twice daily
Trial: NCT00994786
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
Trial: NCT03432468
Drug: Valsartan 1
RxNorm normalized name: valsartan 16 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: the high dose of valsartan
Trial: NCT03432468
Drug: Valsartan 80 mg
RxNorm normalized name: valsartan 80 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a single dose of valsartan
Trial: NCT02001974
Drug: Paclitaxel+Reparixin
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
Trial: NCT01183650
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg, administered orally, daily for 10 days
Trial: NCT03305224
Drug: Ra-223 in combination with enzalutamide
RxNorm normalized name: Radium Ra-223
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
Trial: NCT00366301
Drug: Insulin glargine injection
RxNorm normalized name: Insulin Glargine Injection
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily for 14 weeks
Trial: NCT00366301
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Up to 4 pils per day (2g per day) maximum
Trial: NCT00747526
Drug: Rabeprazole sodium 5 mg
RxNorm normalized name: rabeprazole sodium 5 MG
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
Trial: NCT00747526
Drug: Rabeprazole sodium 10 mg
RxNorm normalized name: rabeprazole sodium 10 MG
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
Trial: NCT03458559
Drug: Radium-223 chloride
RxNorm normalized name: Radium-223 chloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
Trial: NCT01453023
Drug: Fluticasone Furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Trial: NCT03458559
Drug: Rhenium-188-HEDP
RxNorm normalized name: RHENIUM
DrugBank: Rhenium re-186 (DB19266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
Trial: NCT03184090
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palbociclib in combination with endocrine therapy (investigator's choice)
Trial: NCT01453023
Drug: Fluticasone Furoate/Vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Trial: NCT01330693
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
Trial: NCT01755676
Drug: Orlistat 60 mg
RxNorm normalized name: orlistat 60 MG
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet 3 times a day
Trial: NCT01330693
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-active sugar pill randomly assigned at baseline visit
Trial: NCT00003415
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02232399
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Trial: NCT02232399
Drug: Milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Trial: NCT01660256
Drug: OPC-12759
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation, 4 times/day for 4 weeks
Trial: NCT00637468
Drug: Intravenous injection of acetazolamide
RxNorm normalized name: acetazolamide Injection
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003415
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01440127
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
Trial: NCT04468230
Drug: Nicotine Transdermal Patch
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Treatment Condition
Trial: NCT00601432
Drug: levofloxacin oral solution
RxNorm normalized name: Levofloxacin Oral Solution
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02361060
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mcg/kg
Trial: NCT02361060
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg/kg
Trial: NCT02361060
Drug: Atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mcg/kg
Trial: NCT00167232
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01150461
Drug: losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg b.i.d
Trial: NCT04230460
Drug: Cannabis (THC) (Inhaled) Placebo
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis vapor is produced from 500 mg of dried plant material (placebo) (0% THC). Participants will inhale ad libitum over 10 minutes.
Trial: NCT04230460
Drug: Cannabis (High% THC) (Inhaled)
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis vapor is produced from 500 mg of dried plant material (7.5% THC). Participants will inhale ad libitum over 10 minutes.
Trial: NCT04230460
Drug: Cannabis (Very High% THC) (Inhaled)
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis vapor is produced from 500 mg of dried plant material (12.5% THC). Participants will inhale ad libitum over 10 minutes.
Trial: NCT04230460
Drug: Alcohol (oral)
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed to achieve a 0.05% Blood Alcohol Concentration (BAC), so the amount of alcohol consumed will be calculated to produce a peak BAC of 0.065%. Subjects will be served three equal-sized drinks, 10-minutes apart, and be instructed to pace each drink evenly over the 10-minute period.
Trial: NCT04062435
Drug: Drop application in the inferior fornix
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arms
Trial: NCT04062435
Drug: Drop application on the cornea
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arms
Trial: NCT02706951
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; Oral
Trial: NCT02706951
Drug: Placebo Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; Oral
Trial: NCT00494468
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03080142
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
Trial: NCT03080142
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
Trial: NCT02614612
Drug: Itacitinib (200 mg)
RxNorm normalized name: ritlecitinib 50 MG
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02614612
Drug: Itacitinib (300 mg)
RxNorm normalized name: ritlecitinib 50 MG
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02614612
Drug: prednisone or methylprednisolone (corticosteroids)
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
Trial: NCT01743690
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01743690
Drug: fluocinolone
RxNorm normalized name: Fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01841697
Drug: Omarigliptin
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
Trial: NCT01841697
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg oral tablet once a day for 24 weeks
Trial: NCT01841697
Drug: Placebo to omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
Trial: NCT01841697
Drug: Placebo to Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
Trial: NCT01841697
Drug: Open-label Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
Trial: NCT01841697
Drug: Open-label Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
Trial: NCT00678483
Drug: rimonabant (SR141716)
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: once daily
Trial: NCT00511186
Drug: BIAP
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
Trial: NCT04961632
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients taking 20mg tamoxifen will receive dose increments of 10mg every 8 weeks until endoxin threshold of \>30nM or the maximum dose of 40mg/day is reached. The escalated dose will be taken for 1 year before reverting back to 20mg.
Trial: NCT04961632
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take tamoxifen at the ascribed genotype-determined dose as determined in the dose-determination phase.
Trial: NCT00996502
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle
Trial: NCT00996502
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg of Bevacizumab every 3 weeks
Trial: NCT00996502
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg of Erlotinib PO daily days 2-16
Trial: NCT00996502
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg of Prednisone PO bid
Trial: NCT00302159
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally 75mg/m\^2 first day of radiation until completion. Restart 4 weeks post radiation.
Trial: NCT00302159
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
Trial: NCT02790775
Drug: Anti-VEGF in quadrant 1
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02790775
Drug: Anti-VEGF in quadrant 2
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02790775
Drug: Anti-VEGF in quadrant 3
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02790775
Drug: Anti-VEGF in quadrant 4
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00549978
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cilostazol, then cilostazol/probucol
Trial: NCT00549978
Drug: Probucol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol probucol/ cilostazol
Trial: NCT01008163
Drug: YY-351
RxNorm normalized name: Peptide YY
DrugBank: Peptide YY (3-36) (DB05004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT04374383
Drug: Phthalocyanine Dye
RxNorm normalized name: amaranth dye
DrugBank: Phthalocyanine (DB12983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: following LASER assisted SRP, a novel photosensitizer phthalocyanine dye will be placed
Trial: NCT04374383
Drug: LASER assisted SRP
RxNorm normalized name: SRP-6004
DrugBank: SRP-6004 (DB16998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LASER assisted SRP will be carried
Trial: NCT01408810
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
Trial: NCT01241006
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
Trial: NCT01241006
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 60mg PO q day for 5 days
Trial: NCT02632812
Drug: Rebamipide effervescent granules
RxNorm normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Trial: NCT02757313
Drug: Low dose THC marijuana
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02757313
Drug: High dose THC marijuana
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no